2025-02-06 | VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target – Leukemia. Champion, O.; Maïga, S.; Antier, C.; Dousset, C.; Moreau-Aubry, A.; Bellanger, C.; Guillonneau, F.; Descamps, G.; Moreno, J. A.; Kwon,* O.; Lilli, N. L.; Moreau, P.; Chiron, D.; Pellat-Deceunynck, C.; Touzeau, C.; Gomez-Bougie, P.